JP2929331B2
(en)
*
|
1990-07-18 |
1999-08-03 |
丸善石油化学株式会社 |
Fluid for traction drive
|
US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US6281230B1
(en)
*
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US8128963B2
(en)
|
1996-09-27 |
2012-03-06 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating ischemic disorders using carbon monoxide
|
BR9908811A
(en)
*
|
1998-03-16 |
2000-12-05 |
Celgene Corp |
Compound, pharmaceutical composition and its use in the treatment of mammals
|
US7678390B2
(en)
|
1999-04-01 |
2010-03-16 |
Yale University |
Carbon monoxide as a biomarker and therapeutic agent
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
DE19948126A1
(en)
*
|
1999-10-06 |
2001-04-12 |
Max Delbrueck Centrum |
Pharmaceutical agent for the treatment of cachexia and / or cardiogenic shock
|
US8030343B2
(en)
*
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
ES2290091T3
(en)
*
|
2000-11-30 |
2008-02-16 |
The Children's Medical Center Corporation |
SYNTHESIS OF ENANTIOMERS OF 4-AMINO-TALIDOMIDE.
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
KR20040032115A
(en)
|
2001-06-21 |
2004-04-14 |
베쓰 이스라엘 디코니스 메디칼 센터 인크 |
Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
|
EA200401070A1
(en)
|
2002-02-13 |
2005-02-24 |
Бет Изрейэл Диконисс Медикал Сентер, Инк. |
METHODS OF TREATMENT OF VASCULAR DISEASES
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
UA86570C2
(en)
|
2002-04-15 |
2009-05-12 |
Юниверсити Оф Питтсбург Оф Дзе Коммонвелз Систем Оф Хайер Эдьюкейшн |
Method of treating necrotizing enterocolitis
|
CA2482260A1
(en)
|
2002-04-15 |
2003-10-30 |
Beth Israel Deaconess Medical Center Inc. |
Use of heme oxygenase-1 and products of heme degradation
|
US7687079B2
(en)
|
2002-04-15 |
2010-03-30 |
University of Pittsburgh of the Commonwealth System of Higher Education Yale University |
Methods of treating ileus
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
EP1556033A4
(en)
*
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
ES2372273T3
(en)
|
2002-05-17 |
2012-01-17 |
Yale University |
METHODS OF TREATMENT OF HEPATITIS.
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
UA87438C2
(en)
*
|
2002-06-05 |
2009-07-27 |
Йельский Университет |
Method for treatment or prophylaxis of cancer, method for performing of surgical operation for cancer ablation and us of carbon monooxide
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
AU2003228509B2
(en)
|
2002-10-15 |
2008-06-26 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
BR0316057A
(en)
|
2002-11-06 |
2005-09-20 |
Celgene Corp |
Methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis and of reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy or immunotherapy in a patient suffering from a specific cancer, pharmaceutical composition and kit
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
MXPA05005161A
(en)
*
|
2002-11-18 |
2005-07-22 |
Celgene Corp |
Methods of usig and compositions comprising (-)-3- (3, 4- dimethoxy -phenyl)-3 -(1-oxo-1, 3-dihydro- isoindol- 2-yl)- propionamide.
|
CN1738613A
(en)
*
|
2002-11-18 |
2006-02-22 |
细胞基因公司 |
Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
CN1901911A
(en)
*
|
2003-11-06 |
2007-01-24 |
细胞基因公司 |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
NZ547689A
(en)
|
2003-11-19 |
2009-05-31 |
Signal Pharm Llc |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
EP1694328A4
(en)
*
|
2003-12-02 |
2010-02-17 |
Celgene Corp |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
JP2007530544A
(en)
*
|
2004-03-22 |
2007-11-01 |
セルジーン・コーポレーション |
Methods of using immunomodulatory compounds for treating and managing skin diseases or disorders and compositions containing the same
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
EP1744749A4
(en)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
JP2007533761A
(en)
*
|
2004-04-23 |
2007-11-22 |
セルジーン・コーポレーション |
Methods of using immunomodulatory compounds and compositions containing immunomodulatory compounds for treating and managing pulmonary hypertension
|
GB2418427A
(en)
*
|
2004-09-02 |
2006-03-29 |
Univ Cambridge Tech |
Ligands for G-protein coupled receptors
|
ZA200702382B
(en)
*
|
2004-09-03 |
2008-08-27 |
Celgene Corp |
Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
|
EP1811992A2
(en)
*
|
2004-10-28 |
2007-08-01 |
Celgene Corporation |
Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
|
WO2006058008A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
CN100383139C
(en)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
Piperidine-2,6-dione derivatives capable of inhibiting cell from releasing tumor necrosis factor
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
AU2006265019B2
(en)
*
|
2005-06-30 |
2011-10-13 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
US20070038298A1
(en)
*
|
2005-06-30 |
2007-02-15 |
Sulner Joseph W |
Repair of tympanic membrane using placenta derived collagen biofabric
|
WO2007009062A2
(en)
*
|
2005-07-13 |
2007-01-18 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
EP1919365A2
(en)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Ocular plug formed from placenta derived collagen biofabric
|
CA2899923A1
(en)
*
|
2005-08-31 |
2007-03-08 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
RS51840B
(en)
|
2005-09-01 |
2012-02-29 |
Celgene Corporation |
Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(en)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor
|
NZ597304A
(en)
|
2005-10-13 |
2013-06-28 |
Anthrogenesis Corp |
Immunomodulation using placental stem cells
|
KR20080097190A
(en)
*
|
2005-12-29 |
2008-11-04 |
안트로제네시스 코포레이션 |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
CL2007002218A1
(en)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA.
|
US8105634B2
(en)
*
|
2006-08-15 |
2012-01-31 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
CN101534820A
(en)
*
|
2006-09-15 |
2009-09-16 |
细胞基因公司 |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
US20080131522A1
(en)
*
|
2006-10-03 |
2008-06-05 |
Qing Liu |
Use of placental biomaterial for ocular surgery
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
NZ576372A
(en)
|
2006-10-06 |
2012-02-24 |
Anthrogenesis Corp |
Native (telopeptide) placental collagen compositions
|
CN103356711A
(en)
|
2007-02-12 |
2013-10-23 |
人类起源公司 |
Immunomodulation using placental stem cells
|
JP2010518812A
(en)
*
|
2007-02-12 |
2010-06-03 |
アンスロジェネシス コーポレーション |
Hepatocytes and chondrocytes derived from adherent placental stem cells, and enriched cell populations of CD34 +, CD45− placental stem cells
|
MY180812A
(en)
*
|
2007-03-20 |
2020-12-09 |
Celgene Corp |
4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
|
WO2009020590A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CN104211684A
(en)
|
2007-09-26 |
2014-12-17 |
细胞基因公司 |
6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same
|
AU2008307633C1
(en)
|
2007-09-28 |
2015-04-30 |
Celularity Inc. |
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
|
EP2235213A2
(en)
|
2007-12-20 |
2010-10-06 |
Celgene Corporation |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
AU2010229711B2
(en)
|
2009-03-25 |
2015-06-04 |
Celularity Inc. |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
JP5645816B2
(en)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
Pharmaceutical composition comprising core factor related to proliferation and differentiation of central nerve cell
|
EP2851070A1
(en)
|
2010-01-05 |
2015-03-25 |
Celgene Corporation |
A combination of lenalidomide and artesunate/artemisone for treating cancer
|
MX337169B
(en)
|
2010-02-11 |
2016-02-16 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same.
|
MX341050B
(en)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Methods for treating respiratory viral infection.
|
WO2012135299A1
(en)
|
2011-03-28 |
2012-10-04 |
Deuteria Pharmaceuticals Inc |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
WO2012145309A1
(en)
|
2011-04-18 |
2012-10-26 |
Celgene Corporation |
Biomarkers for the treatment of multiple myeloma
|
WO2012149299A2
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporaiton |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
US20150174235A1
(en)
|
2012-06-06 |
2015-06-25 |
Bionor Immuno As |
Vaccine
|
ES2699810T3
(en)
|
2012-06-29 |
2019-02-12 |
Celgene Corp |
Methods to determine the efficacy of drugs using cereblon-associated proteins
|
WO2014018866A1
(en)
*
|
2012-07-27 |
2014-01-30 |
Celgene Corporation |
Processes for preparing isoindoline-1,3-dione compounds
|
US20150038511A1
(en)
|
2012-08-09 |
2015-02-05 |
Celgene Corporation |
Treatment of immune-related and inflammatory diseases
|
CN108938642A
(en)
|
2012-08-09 |
2018-12-07 |
细胞基因公司 |
Immune related and inflammatory disease treatment
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
CA2935495C
(en)
|
2013-01-14 |
2021-04-20 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
AU2014215458A1
(en)
|
2013-02-05 |
2015-08-13 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
WO2014152833A1
(en)
|
2013-03-14 |
2014-09-25 |
Deuterx, Llc |
3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
JP6389241B2
(en)
|
2013-04-17 |
2018-09-12 |
シグナル ファーマシューティカルズ,エルエルシー |
Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
US10245266B2
(en)
|
2014-05-19 |
2019-04-02 |
Celgene Corporation |
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
|
ES2843973T3
(en)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Compositions and methods to induce conformational changes in cereblon and other E3 ubiquitin ligases
|
PL3182996T3
(en)
|
2014-08-22 |
2023-04-17 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
CN107787320B
(en)
|
2015-05-22 |
2020-12-04 |
拜欧赛里克斯公司 |
Protein targeting compounds, compositions, methods and uses thereof
|
SI3313818T1
(en)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
CA3045508A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
CA3061945A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
JP2020526194A
(en)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
Mouse model for assessing toxicity associated with immunotherapeutic agents
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
WO2019099868A2
(en)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
JP2021519337A
(en)
*
|
2018-03-26 |
2021-08-10 |
シー4 セラピューティクス, インコーポレイテッド |
Cereblon binder for the degradation of Ikaras
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
AU2019377854A1
(en)
|
2018-11-08 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
EP3880669A1
(en)
|
2018-11-13 |
2021-09-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
JP2022513062A
(en)
|
2018-11-16 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
Methods of Dosing Manipulated T Cells to Treat B-Cell Malignancies
|
JP2022513685A
(en)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
Methods for Treatment with Adoptive Cell Therapy
|
CN113453679A
(en)
|
2018-12-20 |
2021-09-28 |
C4医药公司 |
Targeted protein degradation
|
PE20212198A1
(en)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
ANTIBODIES AND CHIMERIC RECEPTORS OF SPECIFIC ANTIGENS TO ORPHAN RECEPTOR 1, RECEPTOR TYROSINE KINASE TYPE (ROR1)
|
EP3935050A4
(en)
|
2019-03-06 |
2023-01-04 |
C4 Therapeutics, Inc. |
Heterocyclic compounds for medical treatment
|
JP2024504932A
(en)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス, インコーポレイテッド |
isoindolinone compound
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|